Pepscan appoints chief business officer

Michiel Lodder joins the Dutch firm from OctoPlus

Pepscan Therapeutics, a Dutch biotech company focused on protein mimicry for the discovery of therapeutics peptides and antibodies, has appointed Michiel Lodder as chief business officer.

Lodder joins the firm from OctoPlus, where he was senior manager business development, responsible for licensing, partnering, and alliance management activities.

Pepscan has recently established a number of research collaboration and licensing agreements with major pharma and biotech companies, and Lodder’s experience is expected to enable the firm to add to these partnerships.

You may also like

Research & Development

Pepscan Therapeutics signs agreement with Crucell

Partners aim to develop of novel vaccines to combat infectious diseases
Research & Development

Pepscan agrees research collaboration with Tibotec

Will use CLIPS to develop therapeutic peptides
Research & Development

Immunovo secures seed funding from venture capitalists

Signs partnering agreement with Pepscan, which takes minority interest in Immunovo
Manufacturing

Thermo Fisher Scientific highlights its new accelerator drug development solutions at CPHI Frankfurt 2025

The company has also announced a collaboration with OpenAI as well as a new digital toolbox, OSDPredict, which combines AI and machine learning models to predict formulation behaviour in small-molecule development
Pharmaceutical

Moderna named a top employer by Science for eleventh consecutive year

Moderna was recognised for its commitment to continuous innovation and a culture that reflects the values of its employees.
Pharmaceutical

Pharma leaders to join together to shape the future of the industry at CPHI Frankfurt Leadership Summit

As the pharmaceutical industry enters a defining period of transformation, Informa Markets is hosting an exclusive Leadership Summit at this year’s CPHI Frankfurt, bringing together some of the sector’s most influential executives to address the challenges and opportunities shaping global healthcare
Pharmaceutical

Takeda and Innovent Biologics partner to advance next-gen oncology medicines

Takeda will establish manufacturing of two next-generation late-stage investigational medicines in the US and will receive exclusive commercialisation rights for IBI363 and IBI343 outside the US and China
Subscribe now